Disprin Extra Strength And Disprin Regular Strength 300 mg, 500 mg Tablets
PDF Leaflet Revision Date: 24 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women.
Dosage (summary)
500 mg IM monthly, with an additional 500 mg dose two weeks after the initial dose.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; use effective contraception during treatment.
Key Drug Interactions
- No known drug-drug interactions requiring dose adjustment
Contraindications
- Hypersensitivity to fulvestrant or excipients
- Severe hepatic impairment
- Pregnancy
- Lactation
Common side effects
- Injection site reactions
- Asthenia
- Nausea
- Increased hepatic enzymes
Counselling Points
- Report any hypersensitivity reactions
- Avoid alcohol due to ethanol content
- Caution advised when driving if experiencing asthenia
Serious warnings
- Caution in hepatic and renal impairment
- Risk of thromboembolic events
- Potential for osteoporosis
Important Disclaimer
The Disprin Extra Strength And Disprin Regular Strength 300 mg, 500 mg Tablets professional information leaflet below is the property of Reckitt Benckiser Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
